Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals

Indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals

US Patent 7202207 · Granted Apr 10, 2007

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Bispecific constructs for target and complement engagement2025
Methods of treating complement-mediated disease2025
Single domain antibodies for complement regulation2024
MASP-2, a complement fixing enzyme, and uses for it2016
MASP 2, a complement-fixing enzyme, and uses for it2013
Control device and control method for fixing an information output order for sev2009
Indications of mannan-binding lectin (MBL) in the treatment of immuno-compromise2008
Indications of mannan-binding lectin (MBL) in the treatment of immuno-compromise2008
Masp-2, a complement-fixing enzyme, and uses for it2006
Masp-2, a complement-fixing enzyme, and uses for it2006
MASP-2, a complement-fixing enzyme, and uses for it2006
MASP-2, a complement-fixing enzyme, and uses for it2006